Bausch Health (BHC)
(Delayed Data from NYSE)
$8.71 USD
+0.09 (1.04%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $8.72 +0.01 (0.11%) 7:58 PM ET
2-Buy of 5 2
A Value B Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$8.71 USD
+0.09 (1.04%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $8.72 +0.01 (0.11%) 7:58 PM ET
2-Buy of 5 2
A Value B Growth D Momentum A VGM
Zacks News
Aerie's (AERI) Q4 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Aerie (AERI) reports a wider loss in the fourth quarter, while sales surpass expectations.
Bausch's (BHC) Q4 Earnings Match Estimates, Revenues Miss
by Zacks Equity Research
Bausch (BHC) reports mixed fourth-quarter results, with earnings meeting expectations but sales missing the same.
Should You Buy Bausch Health (BHC) Ahead of Earnings?
by Zacks Equity Research
Bausch Health (BHC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Should Value Investors Pick Bausch Health (BHC) Stock Now?
by Zacks Equity Research
Is Bausch Health (BHC) a great pick from the value investor's perspective right now? Read on to know more.
Aerie's (AERI) Application for Roclanda Accepted in Europe
by Zacks Equity Research
European authorities accept Aerie's (AERI) filing for its second ophthalmology drug, Roclanda.
5 Reasons Why Ironwood Stock Should Be in Your Portfolio
by Zacks Equity Research
We provide five reasons which makes Ironwood (IRWD) a good investment option in 2020.
Bausch's (BHC) Arazlo Gets FDA Approval for Acne Vulgaris
by Zacks Equity Research
Bausch (BHC) gets FDA approval for Arazlo Lotion for the topical treatment of acne vulgaris in patients nine years of age or older.
Top Ranked Value Stocks to Buy for December 13
by Zacks Equity Research
Here are four stocks with buy rank and strong value characteristics for investors to consider today, December 13th
Are You Looking for a Top Momentum Pick? Why Bausch Health (BHC) is a Great Choice
by Zacks Equity Research
Does Bausch Health (BHC) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is Bausch Health (BHC) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Why Is Bausch (BHC) Up 8.2% Since Last Earnings Report?
by Zacks Equity Research
Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Bausch (BHC) Might be Well Poised for a Surge
by Zacks Equity Research
Bausch (BHC) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Moving Average Crossover Alert: Bausch Health Companies
by Zacks Equity Research
Bausch Health Companies is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Generic Drugmakers Gain as Price-Fixing Probe Nears an End
by Indrajit Bandyopadhyay
Shares of generic drugmakers rose on Monday on a possible end to the persistent price-fixing probe.
Top Ranked Value Stocks to Buy for November 26th
by Zacks Equity Research
Here are four stocks with buy rank and strong value characteristics for investors to consider today, November 26th
Is Bausch Health (BHC) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Generic Drugs Industry Turns the Corner on Price Stabilization
by Indrajit Bandyopadhyay
Stabilizing prices of generic drugs are leading to recovery in the industry. New launches are also a boost. However, competition remains stiff.
Will Bausch Health Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Bausch Health.
Aerie (AERI) Q3 Loss Wider, Sales Beat, Guidance Slashed
by Zacks Equity Research
Aerie (AERI) posts a wider-than-expected Q3 loss and lowers guidance.
Is Bausch Health (BHC) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Bausch (BHC) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Bausch (BHC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Bausch (BHC) Beats on Q3 Earnings & Sales, Raises Guidance
by Zacks Equity Research
Bausch (BHC) beats on sales and earnings in the third quarter and raises annual guidance.
Bausch Health (BHC) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Bausch (BHC) delivered earnings and revenue surprises of 12.26% and 2.54%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Bausch Health (BHC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Bausch Health (BHC) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Bausch Health (BHC) stock based on the movements in the options market lately.